PSI partners with Horiba to access characterisation tools

By Nick Taylor

- Last updated on GMT

Related tags: Pharmacology

CRO Particle Sciences (PSI) has formed a strategic partnership with Horiba to use its characterisation tools and service its clients.

PSI acquired a multimodal imaging system from Horiba last year and is now expanding use of its instruments. The strategic alliance ensures PSI, an analytical contract research organisation (CRO), has access to the latest characterisation tools sold by instruments maker Horiba.

It's critical that our analytic and characterisation capabilities keep pace with our formulation expertise​”, said Robert Lee, vice president of pharmaceutical development at PSI. The deal also supports advancements that will be needed as PSI clients scale-up to clinical and commercial.

Partnering with Horiba continues efforts by PSI to strengthen its drug development capabilities through in-house innovation, deals and acquisitions. Over the past 12 months this strategy has seen PSI develop wax nanoparticles, license from SoluBest and buy PEG-based technology.

These developments, like the Horiba deal, strengthened capabilities in areas PSI expects to grow. "The need for particle size analysis and physical characterisation in general is growing rapidly within this highly regulated environment​”, said Lee.

Client referrals

PSI will also benefit from Horiba client referrals. Horiba is often asked by its clients, who range from start-up biotechs to big pharma, to recommend a drug development outsourcing provider. Now, having entered into the strategic alliance, Horiba will refer these clients to PSI.

By entering into this relationship, we can ensure that our clients not only gain access to the most advanced technology, but also that the operators are highly trained to use the instruments to their fullest capability​”, said Mike Pohl, vice president at Horiba.

Collaborating with PSI also strengthens the US-presence of Japan-based Horiba. PSI is located in Bethlehem, Pennsylvania, US and this site will complement the Horiba office in Edison, New Jersey to give the Japanese firm “a strong one-two punch​” to support its East Coast clients.

Related news

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 19-Oct-2020 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us


View more